ABSTRACT
This paper reported a case of a 25-year-old male schizophrenic patient， who obtained remission from psychotic symptoms during the treatment of olanzapine and trihexylphenidyl， was given ziprasidone treatment additionally due to the occurrence of auditory hallucination， and developed stuttering 4 days later. The stuttering disappeared 2 days following the discontinuation of therapy， and reappeared after reinstitution of ziprasidone therapy， but disappeared again after discontinuation. The dose of olanzapine was increased to 20 mg/d to ensure the stability of psychotic remission. At a follow-up visit 4 months later， the patient’s mental condition was stable and stuttering did not recur， indicating that the stuttering was induced by ziprasidone. This case suggests that the possibility of stuttering as an adverse reaction should be considered in the clinical application of ziprasidone.
ABSTRACT
This paper reported a case of drug eruption in a male patient with first-episode schizophrenia. The patient received ziprasidone monotherapy， and experienced post-treatment remission of schizophrenic symptoms， while accompanied by drug eruption with fever and elevated white blood cell count. Even with antiallergic treatment， the eruption did not subside without discontinuation of ziprasidone， whereas the eruption resolved after discontinuation of ziprasidone. This case suggested that individual allergy history should be taken into account during the use of ziprasidone， and timely intervention of adverse skin reactions was essential to prevent the development of severe drug eruption.
ABSTRACT
@#【Objective】To evaluate the efficacy of ziprasidone injection and the related influencing factors for treating agitation in schizophrenic patients based on published literature in English or Chinese. 【Methods】We searched PubMed， EMBASE， Web of Knowledge， Cochrane Library， Wanfang data， Chinese Journal Full- Text Database（CJFD），Chinese Biomedical Literature Database（CBMdisc）and VIP Chinese Technology Periodical Database（VIP）. The Consolidated Standards of Reporting Trials（CONSORT）statement was used as a criterion for screening and assessing the literature. Meta-analysis and meta-regression were conducted by using STATA. With the effect size as the dependent variable and sex，age，baseline PANSS scale total score and oral antipsychotics as the covariates ，the meta- regression model was analyzed. 【Results】The Grades of Recommendation ，Assessment ，Development and Evaluation（GRADE） approach was employed to rate the overall quality of evidence. A total of 14 studies（5 in English and 9 in Chinese）were included in meta analysis and meta regression. The samples were ，respectively，1 197 and 1 149 at baseline and after treatment. Random effect Meta analysis showed that ziprasidone injection had significant efficacy in the treatment of agitation symptoms［SMD=2.04，95%CI（1.47，2.61），P = 0.000］. Meta regression revealed that the efficacy was related to baseline PANSS scores（t = 5.57 ，P = 0.011）and oral antipsychotics（t = 4.07 ，P = 0.027），but irrelevant to age（t = 0.74，P = 0.539）and language published（t = -0.57，P = 0.625）. The efficacy was better in female patients than that in male patients （t = -2.95 ，P = 0.060）. 【Conclusion】 Ziprasidone injection has significant efficacy in schizophrenia patients with agitation symptoms and the efficacy may be enhanced in those patients with higher baseline PANSS score and added with oral antipsychotics.
ABSTRACT
Objective To explore the effects of ziprasidone and clozapine on serum cholinesterase (CHE) concentration in schizophrenia patients. Methods 126 schizophrenia patients were randomly divided into the observation group and the control group. The observation group was treated with ziprasidone. The control group received clozapine. The serum CHE concentration was assayed at 7, 14 and 28 days after treatment. Results ① The PANSS scores in both groups were significantly reduced after treatment, while the control group was lower than the observation group (PANSS score for positive symptoms: 15.3±4.7 vs 22.4±4.8, P<0.01; negative symptoms: 14.6±4.5 vs 21.8±5.2, P<0.01; general psychiatric symptoms: 13.3±3.4 vs 19.2±3.9, P<0.01). ② CHE levels were decreased in both groups after treatment. The control group exhibited greater decrease than the observation group. ③ The observation group had lower adverse reaction rate (34.9%) compared to control group (71.4%). Conclusion ziprasidone has weaker inhibitory effect on CHE activity compared to clozapine. This may explain that ziprasidone has lower therapeutic efficacy and better safety profile.
ABSTRACT
El síndrome neuroléptico maligno es una rara y potencialmente fatal reacción adversa medicamentosa, asociada usualmente al uso de antipsicóticos. Tiene por características la presencia de fiebre, rigidez muscular, estado mental alterado y disfunción autonómica. Los hallazgos de laboratorio son inespecíficos, sin embargo, la presencia de leucocitosis y elevación de la creatina fosfoquinasason hallazgos frecuentes. Presentamos el caso de un paciente varón de 51 años, natural de Lima con antecedentes médicos de tuberculosis pulmonar y esquizofrenia que acude a nuestro hospital con un cuadro de psicosis quien, luego de ser tratado con ziprasidona administrada por vía intramuscular, presentó los síntomas característicos de un síndrome neuroléptico maligno. Conocer la clínica y la fisiopatología de este síndrome nos permitirá un mejor abordaje, ya que por su poca frecuencia podría no llegar a plantearse dentro de los diagnósticos diferenciales, lo que resultaría perjudicial para el paciente.
Neuroleptic malignant syndrome is a rare and potentially fatal drug adverse reaction, usually associated with antipsychotics. Signs and symptoms include: fever, muscle rigidity, altered mental status and autonomic dysfunction. Laboratory findings are nonspecific, however the presence of leukocytosis and elevated creatinine phosphokinase are frequent findings. We present the case of a 51-year-old male patient from Lima with a medical history of pulmonary tuberculosis and schizophrenia that comes to our hospital with psychotic symptoms. After being treated with ziprasidone, administered by intramuscular injection presents with typical symptoms of neuroleptic malignant syndrome. Knowing the clinical features and the pathophysiology of this syndrome will allow us to better approach the condition. Due to its infrequent presentation, it may not be considered within the differential diagnosis, which could be harmful to the patient.
ABSTRACT
Objective To compare the therapeutic effect of different drug in the treatment of schizophrenia in acute stage.Methods From November 2014 to June 2017,105 patients with acute schizophrenia admitted in Department of Psychiatry of Taiyuan Psychiatric Hospital and Department of Psychiatry of Jiuzhou Dermatological Hospital of Taiyuan were selected in the study.Seventy-five patients were from the Department of Psychiatry,Taiyuan Psychiatric Hospital.Thirty patients were from the Department of Psychiatry,Jiuzhou Dermatology Hospital.The patients were divided into three groups by random number method,with 35 cases in each group.A group was given amisulpride.B group was given olanzapine.C group was given ziprasidone.The PANSS score (positive symptoms,negative symptoms,mental pathological score),curative effect (cured,significantly improved,invalid),adverse events (EPS,akathisia,nausea,rapid heart beat,blurred vision,orthostatic dizziness,weight gain,total adverse events) in the three groups were observed.Results After treatment for 2 weeks,the positive symptoms,negative symptoms,mental pathological score in the three groups were significantly decreased (all P ＜ 0.05).The positive symptoms,negative symptoms,mental pathological score at corresponding period had no statistically significant differences among the three groups (all P ＞ 0.05).There was no statistically significant difference in therapeutic effect among the three groups (P ＞0.05).The occurrence of EPS of C group was significantly lower than that of B group [14.29％ (5/35) vs.40.00％ (14/35),x2 =5.851,P ＜ 0.05].The incidence rate of adverse events of C group was significantly lower than that of A group and B group (x2 =5.833,4.690,all P ＜ 0.05).However,there was no statistically significant difference in the occurrence of adverse events between A group and B group(P ＞ 0.05).Conclusion Amisulpride,olanzapine and ziprasidone in the treatment of acute phase of schizophrenia has good early reaction control and late curative effect.The adverse events of ziprasidone is significantly less than the other two drugs.But patients adopt which kind of drugs also need to formulate specific solutions according to individual circumstance.
ABSTRACT
Objective@#To compare the therapeutic effect of different drug in the treatment of schizophrenia in acute stage.@*Methods@#From November 2014 to June 2017, 105 patients with acute schizophrenia admitted in Department of Psychiatry of Taiyuan Psychiatric Hospital and Department of Psychiatry of Jiuzhou Dermatological Hospital of Taiyuan were selected in the study.Seventy-five patients were from the Department of Psychiatry, Taiyuan Psychiatric Hospital.Thirty patients were from the Department of Psychiatry, Jiuzhou Dermatology Hospital.The patients were divided into three groups by random number method, with 35 cases in each group.A group was given amisulpride.B group was given olanzapine.C group was given ziprasidone.The PANSS score (positive symptoms, negative symptoms, mental pathological score), curative effect (cured, significantly improved, invalid), adverse events (EPS, akathisia, nausea, rapid heart beat, blurred vision, orthostatic dizziness, weight gain, total adverse events) in the three groups were observed.@*Results@#After treatment for 2 weeks, the positive symptoms.negative symptoms, mental pathological score in the three groups were significantly decreased (all P<0.05). The positive symptoms.negative symptoms, mental pathological score at corresponding period had no statistically significant differences among the three groups (all P>0.05). There was no statistically significant difference in therapeutic effect among the three groups (P>0.05). The occurrence of EPS of C group was significantly lower than that of B group [14.29%(5/35) vs.40.00%(14/35), χ2=5.851, P<0.05]. The incidence rate of adverse events of C group was significantly lower than that of A group and B group (χ2=5.833, 4.690, all P<0.05). However, there was no statistically significant difference in the occurrence of adverse events between A group and B group(P>0.05).@*Conclusion@#Amisulpride, olanzapine and ziprasidone in the treatment of acute phase of schizophrenia has good early reaction control and late curative effect.The adverse events of ziprasidone is significantly less than the other two drugs.But patients adopt which kind of drugs also need to formulate specific solutions according to individual circumstance.
ABSTRACT
Objective To compare the clinical effects of sodium valproate separately combined with ziprasi -done and olanzapine in the treatment of bipolar disorder type Ⅰ .Methods 100 patients with bipolar disorder type Ⅰ were chosen.According to the digital table ,the patients were randomly divided into two groups ,including A group (50 children) with olanzapine and B group (50 children) with ziprasidone on the basis of sodium valproate .The clinical effects,the BRMS score,digit symbol scores,TMT A/B scores,WCST score and TOH cognitive function scores before and after treatment of the two groups were compared .Results The total effective rates of A group and B group were 88.00％,92.00％,respectively.There was no statistically significant difference in clinical effects between the two groups(χ2 =8.14,P<0.05).The BRMS scores of both two groups after treatment were significantly lower than before treatment(t=3,74,4.06,all P<0.05).There was no statistically significant difference in BRMS score after treatment between the two groups (t =0.89,P >0.05).The digit symbol scores,WCST score and TOH cognitive function scores of B group after treatment were significantly higher than those of A group and before treatment ( t=3.17,4.03,3.96,3.54,2.86,3.81,4.66,4.29,3.81,3.43,all P<0.05).The TMT A/B scores of B group after treatment were significantly lower than those of A group and before treatment ( t=3.82,4.82,4.55,4.09,3.83,all P<0.05).Conclusion Sodium valproate separately combined with ziprasidone and olanzapine in the treatment of bipolar disorder type I possess the same clinical effects in manic symptoms relief ,and sodium valproate combined with ziprasidone can effectively promote the recovery process of cognitive function damage and improve the clinical prognosis for long-term.
ABSTRACT
OBJECTIVE: To evaluate the pharmacokinetics characteristics and safety of antipsytrotic ziprasidone mesylate with single dose intramuscularly injected in healthy volunteers. METHODS: A total of 12 healthy Chinese volunteers(male 6 cases and female 6 cases) were received intramuscularly single dose of ziprasidone mesylate, the dosage was 10 mg.Blood samples were collected at different time after intramuscularly injection.The concentrations of ziprasidone in serum were determined by LC-MS/MS, and the pharmacokinetic parameters were calculated. RESULTS: The concentration-time curves of ziprasidone fitted to two-compartment model.The pharmacokinetic parameters were stated as follows, ρmax was (97.85± 29.24) ng·mL-1;tmax was (0.56±0.30)h;MRT was (5.35±0.96) h; t1/2 was (4.29±0.88)h; AUC0→t was (405.6±98.68) ng·h·mL-1, AUC0→∞was (413.3± 100.69)ng·h·mL-1; CL was (25.50±6.10)L·h-1; Vd was (157.48±47.60)L; Kel was (0.168±0.035)h. There were no significant differences of the parameters between the male and female subjects. The common adverse events were somnolence, nausea and weakness with the severity of mild to moderate. CONCLUSION: The pharmacokinetic parameters in 12 healthy volunteers after intramuscular injection of 10 mg ziprasidone mesylate are in line with that reported in the literature. This medicine has effect of sedation, so that it could be used to control the excited agitation.
ABSTRACT
Objective To compare the influence of ziprasidone and paliperidone on PANSS scores,PRL and body weight of female patients with schizophrenia.Methods 140 female patients with schizophrenia were chosen,and they were randomly divided into group A (70 patients) with ziprasidone and group B (70 patients) with paliperidone.The clinical efficacy,PANSS score,PRL levels and body weight before and after treatment,and incidence of adverse effects were compared between the two groups.Results There was no significant difference in the clinical effects between the two groups (x2 =1.27,P ＞ 0.05).After treatment,the PANSS scores of both two groups were significantly better than those before treatment (t =2.78,3.31,3.06,3.50,2.90,3.38,3.17,3.62,all P ＜ 0.05).There was no significant difference in PANSS score after treatment between the two groups (t =1.08,1.20,0.97,0.88,all P ＞ 0.05).After treatment,the PRL level of group A was significantly higher than that before treatment (t =2.65,P ＜ 0.05).There was no significant difference in PRL level of group B between before and after treatment(t =1.24,P ＞ 0.05).There were no significant differences in the body weight between the two groups (t =1.10,0.97,0.88,all P ＞ 0.05).There was no significant difference in the incidence of adverse reactions between the two groups (x2 =1.03,P ＞ 0.05).Conclusion Ziprasidone and paliperidone in the treatment of female patients with schizophrenia has the same clinical effects and safety;but compared with paliperidone,ziprasidone in the treatment of female patients with schizo-phrenia can efficiently avoid the impact on the PRL levels of patients and reduce the risk of high serum PRL.
ABSTRACT
Objective To investigate the clinical efficacy of ziprasidone in the treatment of first-episode schizophrenia.Methodsfrom January 2014 to June 2016to receive the treatment of patients with first-episode schizophrenia in 156 cases as the research object in the psychiatric hospital, which were randomly divided into two groups, the control group were given risperidone treatment, the observation group was treated with ziprasidone treatment, compared two groups of clinical curative effect of the treatment of patients after.ResultsThe patients in the observation group the total effective rate was 97.4%, the control group total effective rate was 89.7%;group after treatment in patients with negative symptoms score were significantly lower than the control group, with statistical significance between the two groups (P<0.05).ConclusionThe application of ziprasidone in the treatment of first-episode schizophrenia has achieved good clinical efficacy, the total effective rate of treatment is higher, and the negative symptoms are effectively controlled.
ABSTRACT
Objective To explore the effects of ziprasidone combined with psychological intervention on drug related adverse reactions in the treatment of schizophrenia. Methods 62 patients with schizophrenia collected in Shaoxing seventh people's hospital from January 2016 to January 2017 were divided into study group (n=31) and control group (n=31) by single and double digital methods. The control group were received ziprasidone, the study group were received ziprasidone combined with psychological intervention. PANSS score and drug related adverse reactions in the two groups were recorded. Results Before treatment, PANSS score in the two groups has no statistical difference. PANSS score in the study group were decreased significantly than that in the control group (P<0.05). Insomnia or sleepiness, gastrointestinal reactions, headache, dizziness and other drug related adverse reactions in the study goup were significantly lower than those in the control group (P<0.05). Conclusion In schizophrenia treatment, ziprasidone combined with psychological intervention can effectively improve the therapeutic effect on the basis of reducing drug-related adverse reactions.
ABSTRACT
Objective To explore the effects of ziprasidone combined with psychological intervention on drug related adverse reactions in the treatment of schizophrenia. Methods 62 patients with schizophrenia collected in Shaoxing seventh people's hospital from January 2016 to January 2017 were divided into study group (n=31) and control group (n=31) by single and double digital methods. The control group were received ziprasidone, the study group were received ziprasidone combined with psychological intervention. PANSS score and drug related adverse reactions in the two groups were recorded. Results Before treatment, PANSS score in the two groups has no statistical difference. PANSS score in the study group were decreased significantly than that in the control group (P<0.05). Insomnia or sleepiness, gastrointestinal reactions, headache, dizziness and other drug related adverse reactions in the study goup were significantly lower than those in the control group (P<0.05). Conclusion In schizophrenia treatment, ziprasidone combined with psychological intervention can effectively improve the therapeutic effect on the basis of reducing drug-related adverse reactions.
ABSTRACT
OBJECTIVE: The aim of this study was to investigate ziprasidone plasma concentration, daily dose and clinical efficacy and safety in Han Chinese and Mongolian patients with first-episode schizophrenia. METHODS: A total of 123 inpatients affected by schizophrenia were recruited from the Mental Health Center of Inner Mongolia in China. Ziprasidone plasma concentration, clinical efficacy and side effects were systematically evaluated at baseline, and at 1, 2, 4, and 6 weeks. Metabolic measures such as changes in weight, body mass index (BMI), fasting blood glucose (FBG), triglycerides, and cholesterol, were also recorded. RESULTS: 90 patients completed the study. Compared with Han patients, on average, Mongolian patients received a significantly higher ziprasidone dosage for adequate symptom control during the 6-week period and had a lower plasma concentration-to-dose ratio. The Mongolian patients also experienced greater increases in weight and BMI. No significant differences between the two ethnic groups were found in the rate of reduction in the Positive and Negative Syndrome Scale (PANSS) score, Treatment Emergent Symptom Scale (TESS) total score, FBG, triglycerides, cholesterol or Q-Tc interval. CONCLUSION: Compared to Han Chinese patients, Mongolian patients appeared to have increased ziprasidone clearance and require higher doses to achieve effective treatment for schizophrenia.
Subject(s)
Humans , Asian People , Blood Glucose , Body Weight , China , Cholesterol , Ethnicity , Fasting , Inpatients , Mental Health , Plasma , Schizophrenia , Treatment Outcome , TriglyceridesABSTRACT
Objective To investigate the influence of ziprasidone combined with amend electric shock on the efficacy and metabolism of patients with first-episode schizophrenia.Methods According to random number table,86 cases with first-episode schizophrenia from July 2013 to July 2016 in the Second Affiliated Hospital of Xinxiang Medical University were chosen and divided into observation group and control group.The patients in observation group were given ziprasidone combined with first-episode schizophrenia,the patients in control group were taken with olanzapine combined with first-episode schizophrenia.The PANSS total score,CGI score,total efficacy,adverse reaction,body mass index,glycometabolism,and lipid metabolism of two groups were observed and compared.Results The PANSS score,CGI score of two groups were all obvious decreased,which had no significant difference,the total efficacy of two groups had no significant difference;The TESS scores were all decreased,and the TESS score of observation group was obviously lower than that of control group (P ＜ 0.05).Compared with before treatment,the BMI,fasting blood sugar,triglyceride,total cholesterol,high/low density lipoprotein and fasting insulin level of observation group after treatment had no obvious significant difference,while the BMI,fasting blood sugar,triglyceride,total cholesterol,low density lipoprotein,and fasting insulin levels of control group had obvious significant difference,and the BMI,fasting blood sugar,triglyceride,total cholesterol,and fasting insulin of observation group were obviously lower than control group (P ＜ 0.05).Conclusion Olanzapine and ziprasidone combined with amend electric shock have obvious efficacy on patients with first-episode schizophrenia,while the ziprasidone had lower adverse reaction and metabolic side effects,which is worth of clinical promotion and application.
ABSTRACT
Objective To observe the efficacy and safety of domestic ziprasidone injection in the treatment of excitement and agitation in acute period of schizophrenia.Methods 60 patients with schizophrenia excited were randomly divided into two groups,30 cases in each group.The treatment group was given ziprasidone 20 to 40mg/day by intramuscular injection,the control group was given haloperidol 10-20mg/day by intramuscular injection,the two groups were observed for three days.The positive and negative symptoms scale(PANSS)in the excitation factor(EC) points rate was used to assess efficacy,symptoms scale(TESS)was used to evaluate the adverse reaction.Before treatment,2,6,24,48,72 hours after treatment,the positive and negative symptoms scale of excitement factor (PANSS-EC)and symptoms scale(TESS)were evaluated.Results 72 hours after treatment,the PANSS -EC score in the ziprasidone group was obviously lower,the points rate was (69 ±18)%,the total effective rate was 83.3%,which of the haloperidol group were (71 ±26)%,86.7%,the differences between the two groups were not statistically significant (P>0.05).The incidence of adverse reactions between the ziprasidone group and haloperidol group had no statistically significant difference(P>0.05).But in terms of the incidence of vertebral body system,the ziprasidone group(4 cases)was obviously less than the haloperidol group(13 cases),the difference was statistically significant(χ2 =6.65,P<0.05).Conclusion Ziprasidone injection is effective in the treatment of agitation in acute phase of schizophrenia,with less side effect,higher safety.
ABSTRACT
OBJECTIVE:To investigate clinical efficacy and adverse reactions(ADRs)of 4 kinds of the second-generation anti-psychotic drugs in the treatment of acute phase of schizophrenia. METHODS:159 patients with schizophrenia were randomly divid-ed into risperidone group(40 cases),olanzapine group(40 cases),aripiprazole group(39 cases)and ziprasidone group(40 cas-es). All groups were given routine dosage of relevant medicine by routine usage for 6 weeks. Mental status of patients were mea-sured by PANSS before treatment and after 2,4 and 6 weeks of treatment. At the same time,blood glucose,blood lipid,prolac-tion and other metabolic and biological indicators were all detected. RSESE,BARS and UKU were adopted to evaluate ADR. RE-SULTS:A total of 100 patients completed the study. Compared with aripiprazole group and ziprasidone group,risperidone and olan-zapine inhibited symptom more rapidly,with statistical significance (P<0.05). After treatment,body mass index and abdominal circumference of olanzapine group were significantly higher than those of other 3 groups,with statistical significance (P<0.05). Low density lipoprotein of olanzapine group was increased significantly,there was statistical significance compared to ziprasidone group and aripiprazole group(P<0.05). Prolactin level of risperidone group was significantly higher than those of other 3 groups, while that of aripiprazole group was significantly lower than those of other 3 groups,with statistical significance(P<0.05). ADRs of 4 drugs were mild or moderate,most of whom could be alleviated by symptomatic treatment. CONCLUSIONS:In the treatment of acute phase schizophrenia,4 drugs of the second-generation have similar curative effect in symptoms control,among which ris-peridone and olanzapine inhibit positive symptom more rapidly while more ADRs that related to lipid and glucose metabolism and prolactin also show. Aripiprazole and ziprasidone induce less ADRs relatively,and patients show better tolerability. Physicians should consider all kinds of factors in drugs selection,and make individualized treatment plan.
ABSTRACT
Objective To explore the sensitivity regulatory mechanism of ziprasidone capsules on prolactin( PRL) and fast insulin( FINS) in male adolescents with episode schizophrenia.Methods According to inclusion and exclusion criteria, 52 adolescent males selected from January 2015 to March 2016 were confirmed the psychiatric treatment of schizophrenia in our hospital, their ages, ziprasidone capsule usage and suffering schizophrenia stage of disease, height, waist circumference, body weight, hip circumference, and in the morning fasting blood glucose, FINS and PRL content were recorded.Mathematical model were used to calculate QUICKIFINS sensitivity index, and in accordance with the classification criteria BMI, 52 male adolescents with schizophrenia were divided into normal group and overweight group.The correlation detection, and anthropometric parameters, PRL and FINS sensitivity parameters were analysed.Results PRL and FINS, QUICKI indicators were not correlated(r=0.153, P >0.05; r=-0.101, P >0.05) statistically significant; ziprasidone capsule dose has a positive correlation with FINS(r =0.376,P <0.05), and QUICKI negative indicators (r=-0.362,P<0.05); waist-hip ratio or fat content ratio has no correlation with FINS, QUICKI indicators, but BMI and FINS has a positive correlation (r=0.389,P<0.05) and QUICKI indicators with negative correlation(r=-0.413,P<0.05);PRL level between normal group and overweight group was not statistically significant, and levels of FINS in overweight group(10.89 ±8.23) mU/L was higher than the normal group(5.79 ±3.18) mU/L, the difference was statistically significant(P <0.05).QUICKI index between the two groups was statistically significant, and the overweight of FINS was sensitivity less than the normal group.Conclusion Ziprasidone capsule has no relationship with PRL and FINS resistance in the treatment of adolescent patients with schizophrenia, while body mass index correlated with FINS resistance, and ziprasidone capsule dose correlated with FINS resistance.
ABSTRACT
Objective To observe the therapeutic effect of ziprasidone and risperidone on patients with schizophrenia,and analyze the influence on metabolism.Methods 124 patients with schizophrenia were selected and randomly divided into two groups,with 62 cases in each group.They were treated with either ziprasidone or risperidone for both 12 weeks.The PANSS score was compared at the baseline,2 weeks,4 weeks,8 weeks and 12 weeks after ther-apy.The FBG,FINS,HOMA-IR,TG,LDL-C,HDL-C,BMI and prolactin were compared before and after treatment. Results There were 57 and 55 cases completed the study,respectively.There was no difference in PANSS score between 2 groups before and after treatment (P >0.05),although both ziprasidone and risperidone could significantly decrease PANSS (t =6.132,10.323,18.252,23.564,all P 0.05).After treatment,the levels of FBG, FINS,HOMA-IR,TG,BMI and prolactin in ziprasidone group were all significantly increased (t =3.837,12.729, 13.767,4.512,3.176,17.308,all P 0.05).However,there were significant differences between the two groups in FBG,FINS,HOMA-IR,TG, BMI and prolactin after treatment (t =2.511,4.193,7.671,4.439,3.224,16.663,all P <0.05 ).Conclusion Ziprasidone and risperidone both contribute to the alleviation of symptoms in schizophrenia,while ziprasidone has less influence on glucose-lipid metabolism.
ABSTRACT
Objective To observe the effects of ziprasidone and risperidone on schizophrenia patients and the change of serum leptin and adiponectin levels .Methods Totally 80 cases of schizophrenia patients were randomly divided into ziprasidone group and risperidone group ,which were treated for 8 weeks .Measure the positive and negative symptoms scale (PANSS) score and body weight of that number ,leptin and adiponectin at baseline ,treatment 4 weeks and 8 weeks respectively for patients ,at the end of the experiment ,the results for statistical analysis .Results Two groups of 4 ,8 weeks after treatment scores compared with baseline scores dropped significantly ,the difference was statistically significant(P<0 .05) .Risperidone group after treatment ,leptin levels significantly increased body mass index ,and adiponectin levels significantly decreased ,compared with the baseline before treatment was statistically significant difference(P<0 .05) .Conclusion Ziprasidone and risperidone in treatment of schizophrenia have similar efficacy .Ziprasidone has no significant effect on body weight ,leptin and adiponectin levels in treatment of schizophrenia patients . However ,risperidone has a significant effect ,long-term use should pay attention to the side effects .